

# AAIC 2025 Presentations Using ALZpath pTau217 assay

Date	Time	Presentation Type	Poster #	Location	Title
27-Jul	7:30am-4:15pm	Poster	36	Exhibit Hall	Exploratory CSF proteomic analysis of a pre-specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer's disease patients treated with zervimesine
27-Jul	7:30am-4:15pm	Poster	223	Exhibit Hall	Comparison of renal effect on various plasma tau assays in reference to CSF values
27-Jul	7:30am-4:15pm	Poster	252	Exhibit Hall	Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma p-Tau217
27-Jul	7:30am-4:15pm	Poster	256	Exhibit Hall	Divergent trajectories of brain ageing across the seventh decade predict AD pathology in a UK population-based birth cohort
27-Jul	7:30am-4:15pm	Poster	264	Exhibit Hall	CAPS Plus: A clinical biomarker scoring system to predict A $\beta$ positivity and facilitate enrolment in anti-amyloid clinical trials
27-Jul	7:30am-4:15pm	Poster	341	Exhibit Hall	Diagnostic Performance of Plasma Phospho-tau217 for Alzheimer's Disease in a Large Memory Clinic Cohort
27-Jul	7:30am-4:15pm	Poster	342	Exhibit Hall	ApoE Genotyping and 12-Month Longitudinal Tracking of p-Tau217 Using Fingerstick Collection in a Population-Based Cohort
27-Jul	7:30am-4:15pm	Poster	513	Exhibit Hall	Head-to-head trajectories of MK6240, Flortaucipir, and plasma p-tau217 as a function of A $\beta$
28-Jul	7:30am-4:15pm	Poster	261	Exhibit Hall	Accelerated rate of plasma p-Tau217 progression in amyloid- $\beta$ APOE $\epsilon$ 4 carriers
28-Jul	7:30am-4:15pm	Poster	228	Exhibit Hall	Alzheimer's Disease Diagnosis and Plasma Phospho-tau217 (ADAPT) Stage 1
28-Jul	7:30am-4:15pm	Poster	272	Exhibit Hall	Evaluation of Plasma Phosphorylated Tau217 for Differentiating Alzheimer's Disease
28-Jul	7:30am-4:15pm	Poster	299	Exhibit Hall	Remote detection of Alzheimer's disease pathology using a digital sleep and circadian biomarker: an InSleep46 study.
28-Jul	7:30am-4:15pm	Poster	300	Exhibit Hall	The utility of plasma p-tau217 in former American football players at risk for chronic traumatic encephalopathy
28-Jul	7:30am-4:15pm	Poster	308	Exhibit Hall	Head-to-Head evaluation of plasma p-tau217 associations with MK6240, Flortaucipir, PI2620, and RO948 tau PET tracers
28-Jul	7:30am-4:15pm	Poster	332	Exhibit Hall	Plasma proteomic analysis of a biomarker-defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in AD participants
28-Jul	7:30am-4:15pm	Poster	342	Exhibit Hall	Relationship between ALZpath pTau217 and cognitive test performance in a primary care sample
28-Jul	7:30am-4:15pm	Poster	351	Exhibit Hall	Sleep apnea moderation of cortical amyloid- $\beta$ and plasma P-tau217 in ethnically diverse older adults
28-Jul	7:30am-4:15pm	Poster	408	Exhibit Hall	Integration of plasma and imaging data within the ADRC biofluid and imaging ecosystems
28-Jul	7:30am-4:15pm	Poster	865	Exhibit Hall	Plasma phosphorylated tau 217 and amyloid- $\beta$ 42/40 for amyloid risk in subgroups
28-Jul	7:30am-4:15pm	Poster	882	Exhibit Hall	The utility of phosphorylated Tau-217 in discriminating chronic traumatic encephalopathy and Alzheimer's disease in postmortem cerebral spinal fluid and serum.
28-Jul	7:30am-4:15pm	Poster	960	Exhibit Hall	Effects of Processing Deviations on Plasma Concentrations of AD Biomarkers
28-Jul	7:30am-4:15pm	Poster	972	Exhibit Hall	Clinical Utility of Plasma Biomarkers of Alzheimer's Disease (CliPAD)
28-Jul	7:30am-4:15pm	Poster	973	Exhibit Hall	Predicting PET amyloid positivity in the intermediate plasma p-tau217 group
28-Jul	2:00pm-2:10pm	Presentation	N/A	Hall F	Revolutionizing at-home testing of blood-based P-tau217 for early detection of Alzheimer's disease: A validation study of the Tasso Lancet Device
28-Jul	2:20pm-2:30pm	Presentation	N/A	Hall F	The DROP-AD project: AD biomarkers from dry blood spots
28-Jul	2:20pm-2:30pm	Presentation	2-27-FRS-A	Convention Centre	A $\beta$ -dependent trajectories of Braak stages for MK6240 and Flortaucipir tau PET
29-Jul	7:30am-4:15pm	Poster	332	Exhibit Hall	Clinical Utility of Plasma pTau217 and NFL in Dementia Diagnosis and Management in a Taiwanese Memory Clinic
29-Jul	7:30am-4:15pm	Poster	303	Exhibit Hall	Determining Cut points for Clinical Interpretation of Alzheimer's Disease Pathology Using Two Commercial Plasma P-tau217 Immunoassays
29-Jul	7:30am-4:15pm	Poster	445	Exhibit Hall	Prediction of Amyloid Status using EEG-Based Brain Effective Connectivity
29-Jul	8:16-8:20am	Presentation	105	Convention Centre	Plasma Phosphorylated Tau 217 predicts cognitive and functional deterioration across clinical stages of Alzheimer's disease
29-Jul	9:15-9:30am	Presentation	701	Convention Centre	Performance of plasma p-tau217 and NFL in an unselected memory clinic setting
30-Jul	7:30am-4:15pm	Poster	292	Exhibit Hall	Blood biomarkers for Alzheimer's disease are correlated with treatment outcomes in a randomized trial assessing the effects of escitalopram on agitation
30-Jul	7:30am-4:15pm	Poster	271	Exhibit Hall	Comparison of plasma pTau217 assays on different platforms
30-Jul	7:30am-4:15pm	Poster	351	Exhibit Hall	Plasma biomarkers, brain amyloid pathology, and cortical thickness in a racially diverse community cohort: the Human Connectome Project
30-Jul	7:30am-4:15pm	Poster	693	Exhibit Hall	Modifiable dementia risk factors differentially relate to intermediate brain and cognitive outcomes in the population-based Rotterdam Study
30-Jul	5:00-5:15pm	Presentation	105	Convention Centre	Plasma pTau and GFAP are associated with subjective cognitive decline and memory concerns in the remote, digital Brain Health Registry cohort.
31-Jul	9:00am-9:45am	Presentation	701A	Convention Centre	Associations between plasma pTau217, cognitive impairment, and synaptic density in AD vulnerable brain regions